ArticleCureus2025
Complete Pathological Response of Human Papillomavirus (HPV)-Related Oropharyngeal Carcinoma After Primary Treatment With Stereotactic Radiotherapy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCCs) with locally advanced progression are generally treated with curative intent concurrent chemoradiation. This case report of a 51-year-old female highlights the potential for locoregional control with complete pathologic response following primary stereotactic body radiotherapy (SBRT). Previous studies on SBRT for head and neck cancers report variable dose fractionation schemes and inconsistent volume contouring techniques, with most SBRT applications focused on recurrent or post-operative settings rather than definitive primary treatment. In this case, the patient initially presented with palpable left cervical lymphadenopathy. Diagnostic workup confirmed non-keratinizing invasive squamous cell carcinoma of the left base of the tongue, with strong p16 positivity. After declining standard curative intent treatment options, including chemoradiation, the patient later accepted a palliative SBRT regimen of 40 Gy in five fractions weekly, targeting the oropharynx and unilateral neck. The patient ultimately only received 32 Gy in four fractions. Follow-up imaging demonstrated significant tumor regression, but at five months, a palpable L neck mass remained. A subsequent selective neck dissection confirmed complete pathologic response with no residual carcinoma. The patient remained disease-free 68 months after treatment with minimal late toxicities. This case supports the feasibility of using SBRT as a definitive modality for HPV-related OPSCC, highlighting the potential for durable locoregional control with an acceptable toxicity profile. Given the growing interest in both treatment de-escalation for HPV-related OPSCC and the application of SBRT in head and neck cancers, this report suggests a promising, though preliminary, role of SBRT in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.